- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02037568
Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress
Improved Behavioral Outcome in Allogeneic Hematopoietic Stem Cell Transplant Patients by Reducing Caregiver Distress: Behavioral and Physiological Evidence
Study Overview
Detailed Description
Specific Aims
- Create a Community Advisory Board (CAB) consisting of allogeneic HSCT patients, caregivers, blood cancer oncologists, support staff and study investigators to provide input.
- Assess patient Quality of Life (QOL) following an allogeneic HSCT using the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) as the primary patient outcome. Patients whose caregivers receive "fone" PsychoEducation and Relaxation (fPER) will have improved QOL compared to caregivers assigned to treatment as usual (TAU).
- Test the impact of fPER on a caregiver composite distress score (encompasses depression, anxiety, and stress) as the primary caregiver outcome. Caregivers receiving fPER will have reduced distress.
- Assess biomarkers of allostatic load in patients prior to transplant and caregivers during the transplant process using novel biomarkers (hair cortisol and telomeres). fPER will be associated with reduced allostatic load in caregivers compared to TAU. Patient hair cortisol collected only before transplant will relate to QOL at intake.
OUTLINE: Caregivers are randomized to 1 of 2 groups.
All patients and caregivers, regardless of randomization, are informed of what to expect during the transplant process and how to locate available support resources within each program. Patients and caregivers are given information that is specific to their involvement in the transplantation process and recovery phase.
- Group I (treatment as usual [TAU]): Subjects randomized to TAU will be encouraged to participate in available support programs at their respective centers which are very similar between sites and include individual counseling as well as support groups. Due to the impact of our prior intervention on caregiver distress, we will provide each caregiver randomized to TAU a workbook prepared for someone to use without inclusion of one-on-one sessions with a therapist.
- Group II (PsychoEducation and Relaxation [fPER]): Caregivers will participate in the fPER intervention prior to transplant. The fPER consists of 10 sessions to include 4 weekly 60-minute sessions followed by 4 biweekly 60-minute sessions and two additional sessions between day 100 and 6 months post-transplant. Each fPER session will be devoted to a separate topic with the goal of assisting the caregiver in the development and application of stress-management coping skills including learning problem-solving skills, identifying cognitive distortions, application of relaxation techniques, use of the emWave2, coping skills training, effective use of social support, and establishing appropriate goals. All caregivers in fPER will be provided a Caregiver Workbook that includes information about the session topics and homework assignments. fPER sessions will be delivered either at the clinic during patient visits or via video chat. fPER will also include incorporation of Smartphone technology to make the interventionist available by video chat.
Caregivers and patients undergo psychosocial assessments prior to randomization, and at 6 weeks, 3 months and 6 months after transplant (anchored to the day of transplant as day 0). At each phase, patients and caregivers will complete the same battery of questionnaires that includes the Center for Epidemiological Studies-Depression scale (CES-D), the perceived stress scale (PSS), and the State-Trait Anxiety Inventory (STAI). Additionally the patient will complete the FACT-BMT each time while the caregiver completes the Caregiver Reaction Assessment (CRA) and Carer Support Needs Assessment Tool (CSNAT). The patient and the caregiver will additionally complete a demographic questionnaire that includes questions regarding age, diagnosis, income, and other standard questions regarding nutrition, health behaviors, and health services utilization. At study completion, an exit questionnaire will address each subject's evaluation of the study and the group in which they were assigned.
Blood and hair samples from caregivers will be collected every three months: baseline (patient and caregiver), 3 (caregiver) and 6 (patient and caregiver) months post-transplant.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital
-
Denver, Colorado, United States, 80218
- Presbyterian/St. Luke's Medical Center (PSLMC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
DISEASE CHARACTERISTICS (Meets all of the following criteria):
- Patient undergoing allogeneic hematopoietic stem cell transplant (HSCT)
- Caregiver: the person in the patient's life who is primarily responsible for care decisions, emotionally invested in the patient's care, provides instrumental care such as transportation, and available if randomized to the fPER group to participate in the majority of intervention sessions
PATIENT CHARACTERISTICS:
- Able to read and speak English
- Has telephone access
CAREGIVER CHARACTERISTICS:
- Able to read and speak English
- Willingness to use a Smartphone
- No serious medical condition likely to influence cortisol assessment in their hair
- Alcohol consumption limited to < 2 drinks/day
- At least 18 years of age
Exclusion Criteria:
PRIOR CONCURRENT THERAPY:
- No history of a psychiatric illness unrelated to the HSCT within the past 18 months
- No steroid medications (caregiver)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Caregiver Self-Directed
Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
|
|
Experimental: Caregiver Intervention
Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
|
Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups.
Manualization is crucial for successful wider implementation.
Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the "new normal."
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Treatment - Blood/Marrow Transplant
Time Frame: Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
"Functional Assessment of Cancer Treatment - Blood/Marrow Transplant" (FACT-BMT) is used to assess the life quality of patients.
The scale includes 5 subscales.
The scores of each scale are summed to compute a total score.
The scale range is 0-148.
Higher score indicates better life quality.
|
Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Caregiver Distress - Principal Component Analysis
Time Frame: Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Caregiver Distress is a composite score is created from a principal component analysis (PCA).
This PCA extracted the first principal component from summary variables of Center for Epidemiological Studies Depression Scale, Spielberger State and Trait Anxiety Inventory, and Perceived Stress Scale.
The composite distress score has a mean of 0.0 and SD of 1.0, scale ranges from -2.06 - 3.73.
Higher score indicates greater distress.
|
Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived Stress Scale
Time Frame: Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
The "Perceived Stress Scale" (PSS) measures the overall level of stress.
This instrument contains 14 items accessing overall appraisals of stress in the past month.
The total score range is 0-56.
A higher score indicates greater stress.
|
Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Center for Epidemiological Studies Depression Scale
Time Frame: Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
"Center for Epidemiological Studies Depression" Scale (CESD) is a self-report 20-item scale designed to measure current depressive symptoms.
Total score range from 0-60, with a score at or above 16 reflecting significant depressive symptomatology.
|
Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Spielberger State-Trait Anxiety Inventory
Time Frame: Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
The "Spielberger State and Trait Anxiety Inventory" (STAI) is a validated self-reporting instrument used to assess anxiety in adults.
The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety).
The scale consists of 20 questions, and a higher score indicates greater anxiety.
Total score ranges from 20 (no anxiety) to 80 (maximum anxiety).
|
Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Change in Adrenal Activity Over Time
Time Frame: Baseline (prior to transplant), 3 months (caregiver only), and 6 months after transplant.
|
Cortisol measured in hair will be used as a retrospective measure of activation of the hypothalamic pituitary adrenal axis.
Because hair cortisol were not normally distributed, the data were log transformed.
|
Baseline (prior to transplant), 3 months (caregiver only), and 6 months after transplant.
|
Change in Caregiver Telomere Length Over Time
Time Frame: Baseline (prior to transplant), 3 months and 6 months after transplant
|
Telomere length was assessed as a measure of cellular aging in blood samples from participants.
Because telomere length were not normally distributed, the data were log transformed.
|
Baseline (prior to transplant), 3 months and 6 months after transplant
|
Change in Caregiver Telomerase Activity Over Time
Time Frame: Baseline (prior to transplant), 3 months and 6 months after transplant
|
Telomerase activity will be assessed as a measure of the ability to reverse cellular aging processes.
Because telomerase activity were not normally distributed, the data were log transformed.
|
Baseline (prior to transplant), 3 months and 6 months after transplant
|
Caregiver Reaction Assessment
Time Frame: Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
The "Caregiver Reaction Assessment" (CRA) is a measure of caregiver burden.
This instrument contains 24 items reflecting the total caregiver situation in the past month.
The scale includes 5 subscales.
The scores of each scale are summed to compute a total score.
Minimum score (best value)=5.
Maximum score (worst value)=25.
Higher values reflect the experience of a higher burden.
|
Baseline (prior to transplant), 6 weeks, 3 months and 6 months after transplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark L Laudenslager, PhD, University of Colorado Denver (Anschutz Medical Campus)
Publications and helpful links
General Publications
- Sannes TS, Ranby KW, Yusufov M, Brewer BW, Jacobs JM, Callan S, Ulrich GR, Pensak NA, Natvig C, Laudenslager ML. More often than not, we're in sync: patient and caregiver well-being over time in stem cell transplantation. Health Qual Life Outcomes. 2022 Jan 10;20(1):6. doi: 10.1186/s12955-021-01909-3.
- Laudenslager ML, Simoneau TL, Mikulich-Gilbertson SK, Natvig C, Brewer BW, Sannes TS, Kilbourn K, Gutman J, McSweeney P. A randomized control trial of stress management for caregivers of stem cell transplant patients: Effect on patient quality of life and caregiver distress. Psychooncology. 2019 Aug;28(8):1614-1623. doi: 10.1002/pon.5126. Epub 2019 May 25.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 13-2639
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic/Lymphoid Cancer
-
Leland MethenyAvailableHematopoietic/Lymphoid CancerUnited States
-
ImCheck TherapeuticsRecruitingHematopoietic/Lymphoid Cancer | Solid Tumor, AdultFrance, Belgium, United States, Germany, Spain, United Kingdom
-
M.D. Anderson Cancer CenterAmgenTerminatedHematopoietic/Lymphoid Cancer | Richter's TransformationUnited States
-
Cancer Research UKUnknownHematopoietic/Lymphoid CancerUnited Kingdom
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedPain | Hematopoietic/Lymphoid CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer | SurvivorshipUnited States
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownHematopoietic/Lymphoid CancerFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid System NeoplasmUnited States